

# *Contrast Pd/Pa* **Better than resting measures?**

Nils P. Johnson, MD, MS, FACC  
Associate Professor of Medicine

Division of Cardiology, Department of Medicine  
and the Weatherhead PET Imaging Center  
University of Texas Medical School at Houston  
Memorial Hermann Hospital – Texas Medical Center  
Houston, Texas, United States of America

# Disclosure Statement of Financial Interest

Within the past 12+ months, Nils Johnson has had a financial interest/arrangement or affiliation with the organization(s) listed below.

## Affiliation/Financial Relationship

- Grant/Research Support  
(to institution)
- Educational organizations  
(travel support for academic meetings  
but never honoraria)

## Organizations (alphabetical)

- St Jude Medical (for CONTRAST study)
- Volcano/Philips (for DEFINE-FLOW study)
- ASNC (travel award, 2007)
- Canadian CPI (Montréal, 2013-15)
- CRF (TCT 2012-14, CPIIS 2014)
- ESC (ETP physiology courses, 2013-15)
- KSIC (annual meeting, 2015)
- SCAI (travel award, 2010)


Nils Johnson has never personally received any money from any commercial company. Specifically, he does not accept commercial consulting, travel, entertainment, or speaking compensation of any kind.

# Necessity of hyperemia


## Experimental Basis of Determining Maximum Coronary, Myocardial, and Collateral Blood Flow by Pressure Measurements for Assessing Functional Stenosis Severity Before and After Percutaneous Transluminal Coronary Angioplasty

Nico H.J. Pijls, MD; Jacques A.M. van Son, MD; Richard L. Kirkeeide, PhD; Bernard De Bruyne, MD; and K. Lance Gould, MD

**[FFR] applies only to maximally dilated conditions when all resistances are constant and the derivation of flow reserve from pressure is possible.**



**FAME 1**



**FAME 2**

**Table 3 I** Use of fractional flow reserve, intravascular ultrasound, and optical coherence tomography in SCAD

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
FFR is recommended to identify hemodynamically relevant coronary lesion(s) when evidence of ischaemia is not available.	I	A	399, 401, 405

**Class I/A from ESC**

Quote = Pijls NH, *Circulation*. 1993 Apr;87(4):1354-67 (text from discussion)

FAME 1 = Tonino PA, *NEJM*. 2009 Jan 15;360(3):213-24 (Figure 3A)

FAME 2 = De Bruyne B, *NEJM*. 2014 Sep 25;371(13):1208-17 (Figure 1A)

# No hyperemia $\approx$ 80% accuracy

- Rest Pd/Pa
  - Mamas, 528 lesions, accuracy not reported, 0.86 AUC
  - RESOLVE, 1593 lesions, 82% accuracy, 0.82 AUC
  - VERIFY 2, 120 lesions, 85% accuracy, 0.89 AUC
- iFR
  - RESOLVE, 1593 lesions, 80% accuracy, 0.81 AUC
  - ADVISE 2, 690 lesions, 82% accuracy, 0.90 AUC
  - VERIFY 2, 120 lesions, 82% accuracy, 0.87 AUC


Mamas = Mamas MA, *J Invasive Cardiol.* 2010 Jun;22(6):260-5

RESOLVE = Jeremias A, *JACC.* 2014 Apr 8;63(13):1253-61

ADVISE 2 = Escaned J at TCT 2013 in San Francisco on October 30, 2013


VERIFY 2 = Watkins S at SCAI 2014 in Las Vegas on May 30, 2014

# No physiology <70% accuracy



4,086 lesions with QCA  
Compared to  $\text{FFR} \leq 0.8$


- 50% DS threshold
  - 0.64 AUC



1,066 lesions with QCA  
Compared to  $\text{FFR} \leq 0.8$


- 52% DS threshold
  - 66% accuracy
  - 0.66 AUC

# Pyramid of diagnostic accuracy






# Pyramid of diagnostic accuracy




# Pyramid of diagnostic accuracy





# Pyramid of diagnostic accuracy



# Vasodilators in human physiology

- dipyridamole (1978, Gould KL, *Am J Cardiology*)
- *contrast medium (1983, Ganz P, Am Heart J)*
- coronary occlusion (1984, Marcus ML, *NEJM*)
- papaverine (1986, Wilson RF, *Circulation*)
- adenosine (1990, Wilson RF, *Circulation*)
- ATP (2003, De Bruyne B, *Circulation*)
- nitroprusside (2004, Kern MJ, *Circulation*)
- nicorandil (2006, Kang JC, *Int J Cardiology*)
- regadenoson (2011, Nair PK, *JACC Interventions*)

# 1959 paper on contrast hyperemia


*Effects on Coronary Blood Flow.*—A total of 48 observations in 5 dogs was made on the effects of intracoronary contrast injections on coronary blood flow. Each dog received 2 to 4 injections of each of the dyes (0.025 to 0.25 c.c./Kg). Injections were given only when coronary blood flow varied less than 5 per cent over a period of 5 minutes. Immediately following the response, sufficient time was allowed for the coronary blood flow to return to the preinjection rate. The results indicate that all of the contrast media increased coronary blood flow, averaging a 60 per cent increase from the control.

70 kg \* (0.025 to 0.25 cc/kg) =

1.8 to 18cc  $\approx$  10cc of IC contrast

gave 60% increase in flow

# 1974 introduction of CFR




# 1983 and 1985 coronary $\Delta P$ in humans


**Table 1.** Effect of intracoronary injection of Renograffin 76 on mean coronary stenosis pressure gradients

% Angiographic stenosis	Gradient at rest (mm Hg)	Gradient after Renograffin 76 (mm Hg)
30% LM	0	0
30% RCA	6	17
50% Graft	0	0
50% LAD	0	3
50% LAD	5	21
55% LAD	0	27
60% RCA	0	0
60% LAD	5	20
60% LAD	8	24
60% LAD	10	23
65% LAD	13	34
70% LAD	26	37
75% LAD	16	34
80% LAD	0	22
80% LAD	16	30
80% LAD	17	48
80% RCA	25	44
85% CX	7	20
85% RCA	8	26
85% CX	24	38
85% LAD	52	52
85% LAD	57	60
90% LAD	37	41
90% LAD	40	58
90% LAD	41	51
90% LAD	43	60
90% LAD	57	59
90% LAD	50	61
	20 $\pm$ 4 (Mean $\pm$ SE)	33 $\pm$ 4 (Mean $\pm$ SE)

Abbreviations: LAD = left anterior descending; LM = left main; RCA = right coronary artery; CX = circumflex.



# 2015 contrast hyperemia



“8 mL IC bolus  
administration of ...  
contrast medium  
(iodixanol 270 mg/mL)”

- *59% of maximum flow*




# 2003 contrast Pd/Pa

“intracoronary bolus administration of *6 mL of Iohexol* did produce a *significantly weaker effect* than all other stimuli”

- 10 seconds to effect

- 2 second plateau

(vs 22 for papaverine, or 5-7 for adenosine)



**Figure 2.** Individual values of  $P_d/P_a$  ratios in the 21 study patients from group 1 at baseline and during vasodilation induced by the different vasodilators. BL indicates baseline; other abbreviations as in Figure 1.




# 2014 contrast Pd/Pa

- 328 lesions (Spain), ESC abstract P6374
  - cutoff 0.90, ROC area 0.92
- 104 lesions (Italy), RINASCI
  - cutoff 0.83, ROC area 0.97
- 102 lesions (France), ESC abstract P4541
  - cutoff 0.85, ROC area 0.92, 86% accuracy
- 98 lesions (Portugal), ESC abstract P4537
  - cutoff 0.84, ROC area 0.97, 90% accuracy

# Motivations for contrast Pd/Pa

- Contrast Pd/Pa *might* provide superior diagnostic performance than Pd/Pa or iFR
- As operators document FFR wire position anyway, contrast Pd/Pa *potentially* offers valuable information at no extra cost and time
- In *rare centers* adenosine is *expensive* or *not available*, and in *rare patients* adenosine is *contraindicated*
  - Here, contrast Pd/Pa *could* increase feasibility, reduce cost, and improve adoption of functional testing of CAD severity as endorsed by guidelines

# Pyramid of diagnostic accuracy



# CONTRAST study

*ClinicalTrials.gov*

A service of the U.S. National Institutes of Health

[Find Studies](#) ▾

[About Clinical Studies](#) ▾

[Submit Studies](#) ▾

[Resources](#) ▾

[About This Site](#) ▾

[Home](#) > [Find Studies](#) > Study Record Detail

## CONTRAST (Can cONTRast Injection Better Approximate FFR compAred to Pure reSTing Physiology?)

**This study is enrolling participants by invitation only.**

**Sponsor:**

The University of Texas Health Science Center, Houston

**Collaborator:**

St. Jude Medical

**Information provided by (Responsible Party):**

Nils Johnson, The University of Texas Health Science Center, Houston

**ClinicalTrials.gov Identifier:**

NCT02184117

First received: July 2, 2014

Last updated: July 17, 2014

Last verified: July 2014

[History of Changes](#)

[Full Text View](#)

[Tabular View](#)

[No Study Results Posted](#)

### ► Purpose

The purpose of this study is to determine the diagnostic performances of iodine contrast medium and resting conditions to predict fractional flow reserve (FFR). Reference FFR will be measured using standard adenosine. **We hypothesize that contrast FFR will offer superior diagnostic agreement compared to resting conditions.**



URL <https://clinicaltrials.gov/ct2/show/NCT02184117>, accessed April 8, 2015



# Hypothesis

- Contrast Pd/Pa *agrees with adenosine FFR better than resting metrics* (rest Pd/Pa or iFR)
- Unique features of current study
  - Larger *sample size* (improves precision)
  - International and *multicenter* (widely applicable)
  - Blinded *core lab analysis* (minimizes bias)
  - Pragmatic protocol (*real-world scenarios*)
  - Two measurements (*test/retest stability*)
  - *IC and IV adenosine* (route of hyperemia)
  - Rest Pd/Pa and iFR (*both resting metrics*)

# CONTRAST: participating centers

## *Belgium (Aalst)*

- B De Bruyne
- E Barbato

## *Netherlands (Eindhoven)*

- N Pijls
- F Zimmermann

## *USA*

- *W Fearon (Palo Alto)*
- G Chrysant (OKC)

## *France (Lyon)*

- G Rioufol

## *Portugal (Lisbon)*

- S Baptista

## *UT-Houston (sponsor)*

- *N Johnson*
- R Kirkeeide
- KL Gould

## *Italy (Naples)*

- G Esposito
- B Trimarco

## *Scotland (Glasgow)*

- C Berry
- K Oldroyd

## *CRF (physiology core lab)*

- A Jeremias
- A Maehara
- M Matsumura

## *Korea (Seoul)*

- BK Koo (SNUH)
- SJ Park (Asan)

## *Sweden (Stockholm)*


- N Witt

# CONTRAST study: methods


- *750 subjects* with 1 lesion/patient
- Any lesion fulfilling a *clinical indication for FFR*
- *6 to 10 mL* of IC contrast (per operator preference)
- Contrast medium *per local practice*
- Protocol steps (*see example on next slide*)
  - Resting period (at least 1 minute)
  - IC contrast, then IC and/or IV adenosine (each repeated)
  - Pull back wire to guide (check for drift)
- *Tracings blinded* then its parts sent to the core lab




# CONTRAST example: protocol




# CONTRAST example: IC contrast #1




# CONTRAST example: IC contrast #2




# CONTRAST example: IC adeno #1




# CONTRAST example: IC adeno #2



# CONTRAST example: IV adeno #1




# CONTRAST example: IV adeno #2





# CONTRAST example: drift check



# CONTRAST example: summary

- Rest
  - $Pd/Pa = 0.94$  and  $0.95$
  - $iFR = 0.92$  and  $0.93$
- IC contrast
  - $0.84$  and  $0.85$
- IC adenosine
  - $0.77$  and  $0.77$
- IV adenosine
  - $0.76$  and  $0.76$
- Drift check
  - $1.02$  at guide

# CONTRAST study: TCT



## CONTRAST FFR Case presentation

Dr Paul Rocchiccioli

Prof Keith Oldroyd

Prof Colin Berry

Golden Jubilee National Hospital

TCT 2014 taped case

September 13, 2014

Presented by

Dr. Keith Oldroyd

# CONTRAST study: EuroPCR



## The **CONTRAST** Study

Can **contrast** injection better approximate **FFR** compared to pure **resting** physiology?

On behalf of the CONTRAST investigators

ClinicalTrials.gov Identifier: NCT02184117



*EuroPCR 2015*

Late-breaking trial

May 19, 2015

Coronary physiology

“Hot line”

13:40 – 15:10

# Pyramid of diagnostic accuracy

